{"id":58681,"date":"2024-01-06T07:05:14","date_gmt":"2024-01-06T06:05:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/"},"modified":"2024-01-06T07:05:14","modified_gmt":"2024-01-06T06:05:14","slug":"pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/","title":{"rendered":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nCompany Completing 3-year Prospective, Multicenter, Clinical Study<\/li>\n<li>\nAI Integrated Urine Based Liquid Biopsy with High Sensitivity and Specificity<\/li>\n<li>\nNew study to Include 10 Additional Cancer Types<\/li>\n<\/ul>\n<p>DELRAY BEACH, Fla.&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pangiabiotech.com&amp;esheet=53878277&amp;newsitemid=20240105716381&amp;lan=en-US&amp;anchor=PanGIA+Biotech&amp;index=1&amp;md5=86d1daf0e1ab772e782cac72cb5b08a0\" rel=\"nofollow noopener\" shape=\"rect\">PanGIA Biotech<\/a>, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy. This announcement comes as the company prepares to launch additional clinical studies in multi-cancer early detection using the PanGIA<sup>\u00ae<\/sup> Liquid Biopsy Platform. \u201cThe PanGIA urine based true liquid biopsy technology has been developed for global impact by diagnosing, monitoring, and managing cancers earlier to save lives using urine as the sample type to create vastly improved availability and scalability in cancer diagnostics,\u201d according to PanGIA Biotech\u2019s CEO, Holly Magliochetti.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/5\/PanGIA_1_%282%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/5\/PanGIA_1_%282%29.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/22\/PanGIA_1_%282%29.jpg\"><\/a><\/p>\n<p>\nIn 2020, the company received IRB approval and launched a novel AI integrated urine based liquid biopsy study. The company immediately began recruiting urologists in US-based academic as well as large and small group community practices to enroll men who were scheduled for prostate biopsy. Results of the study are pending publication.<\/p>\n<p>\n\u201cBased on the high sensitivity and high specificity of the PanGIA prostate study, PanGIA Biotech is now preparing to significantly expand the platform by launching follow-on studies in ten additional cancer types,\u201d said Tricia Schumann, Chief Investment Officer of PanGIA Biotech. Additional cancer types in the PanGIA follow-on study will include breast, ovarian, lung, renal, bladder, colorectal, stomach, pancreas, liver, and brain. The company will begin recruiting experienced medical professionals across the United States as clinical study sites as well as listing the study on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2FClinicalTrials.gov&amp;esheet=53878277&amp;newsitemid=20240105716381&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=2&amp;md5=25c9c72d16f82cb21e2c9ac270dcece9\" rel=\"nofollow noopener\" shape=\"rect\">ClinicalTrials.gov<\/a>.<\/p>\n<p>\nPanGIA Biotech intends to launch the expanded study in mid-2024. Interested researchers may contact the company for additional information.<\/p>\n<p>\n<b>About PanGIA Biotech, Inc.<\/b><\/p>\n<p>\nPanGIA Biotech develops novel, AI integrated, true liquid biopsy technology that is scalable for global impact. The PanGIA<sup>\u00ae<\/sup> platform allows rapid development of non-invasive testing for detecting, monitoring response to therapy, and managing a variety of diseases and disorders, including cancers as early as Stage 1. The company combines expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns using proprietary technology. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.PanGIABiotech.com&amp;esheet=53878277&amp;newsitemid=20240105716381&amp;lan=en-US&amp;anchor=www.PanGIABiotech.com&amp;index=3&amp;md5=d85f7f3f8272b6c908b4073c64ee3527\" rel=\"nofollow noopener\" shape=\"rect\">www.PanGIABiotech.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Company<br \/>\n<br \/><\/b>Holly Magliochetti<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x43;&#x6f;&#110;&#x74;&#x61;&#99;&#x74;&#x40;&#80;&#x61;&#x6e;&#71;&#x49;&#x41;&#66;&#x69;&#x6f;&#116;&#x65;&#x63;h&#x2e;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">Co&#110;&#116;&#97;&#x63;&#x74;&#x40;&#x50;an&#71;&#73;&#65;&#x42;&#x69;&#x6f;&#x74;ec&#104;&#46;&#99;&#x6f;&#x6d;<\/a><\/p>\n<p>\nMedia Inquiries:<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#x6c;&#116;&#x6f;&#58;M&#x65;&#100;i&#x61;&#64;P&#x61;&#110;G&#x49;&#65;&#x42;&#x69;&#111;&#x74;&#x65;&#99;&#x68;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#77;&#101;&#x64;i&#97;&#x40;&#x50;a&#110;&#x47;&#x49;A&#66;&#x69;o&#116;&#x65;&#x63;h&#46;&#x63;&#x6f;m<\/a><\/p>\n<p>\nInvestor Relations:<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x49;&#x52;&#x40;&#x50;&#97;&#110;&#71;&#73;&#65;&#66;&#105;otech&#46;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x49;&#x52;&#x40;&#x50;&#x61;&#x6e;&#x47;&#x49;&#x41;&#x42;&#x69;&#x6f;&#x74;&#x65;&#x63;&#x68;&#x2e;&#x63;&#x6f;&#x6d;<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company Completing 3-year Prospective, Multicenter, Clinical Study AI Integrated Urine Based Liquid Biopsy with High Sensitivity and Specificity New study to Include 10 Additional Cancer Types DELRAY BEACH, Fla.&#8211;(BUSINESS WIRE)&#8211;PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-58681","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company Completing 3-year Prospective, Multicenter, Clinical Study AI Integrated Urine Based Liquid Biopsy with High Sensitivity and Specificity New study to Include 10 Additional Cancer Types DELRAY BEACH, Fla.&#8211;(BUSINESS WIRE)&#8211;PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-06T06:05:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study\",\"datePublished\":\"2024-01-06T06:05:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240105716381\\\/en\\\/1990700\\\/21\\\/PanGIA_1_%282%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/\",\"name\":\"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240105716381\\\/en\\\/1990700\\\/21\\\/PanGIA_1_%282%29.jpg\",\"datePublished\":\"2024-01-06T06:05:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240105716381\\\/en\\\/1990700\\\/21\\\/PanGIA_1_%282%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240105716381\\\/en\\\/1990700\\\/21\\\/PanGIA_1_%282%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/","og_locale":"en_US","og_type":"article","og_title":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend","og_description":"Company Completing 3-year Prospective, Multicenter, Clinical Study AI Integrated Urine Based Liquid Biopsy with High Sensitivity and Specificity New study to Include 10 Additional Cancer Types DELRAY BEACH, Fla.&#8211;(BUSINESS WIRE)&#8211;PanGIA Biotech, a US based biotechnology company with a mission to develop true liquid biopsy technology that is scalable for global impact, today announced that it ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/","og_site_name":"Pharma Trend","article_published_time":"2024-01-06T06:05:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study","datePublished":"2024-01-06T06:05:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/","url":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/","name":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg","datePublished":"2024-01-06T06:05:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240105716381\/en\/1990700\/21\/PanGIA_1_%282%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pangia-biotech-plans-expanded-multi-cancer-early-detection-liquid-biopsy-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"PanGIA Biotech Plans Expanded Multi-Cancer Early Detection Liquid Biopsy Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=58681"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/58681\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=58681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=58681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=58681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}